Drug therapies in severe asthma - the era of stratified medicine

Kathy J. Hetherington, Liam Heaney

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


Difficult-to-treat asthma affects up to 20% of patients with asthma and is associated with significant healthcare cost. It is an umbrella term that defines a heterogeneous clinical problem including incorrect diagnosis, comorbid conditions and treatment non-adherence; when these are effectively addressed, good symptom control is frequently achieved. However, in 3–5% of adults with difficult-to-treat asthma, the problem is severe disease that is unresponsive to currently available treatments. Current treatment guidelines advise the ‘stepwise’ increase of corticosteroids, but it is now recognised that many aspects of asthma are not corticosteroid responsive, and that this ‘one size fits all’ approach does not deliver clinical benefit in many patients and can also lead to side effects. The future of management of severe asthma will involve optimisation with currently available treatments, particularly corticosteroids, including addressing non-adherence and defining an ‘optimised’ corticosteroid dose, allied with the use of ‘add-on’ target-specific novel treatments. This review examines the current status of novel treatments and research efforts to identify novel targets in the era of stratified medicines in severe asthma.
Original languageEnglish
Pages (from-to)452-456
JournalClinical medicine (London, England)
Issue number5
Publication statusPublished - 05 Oct 2015


Dive into the research topics of 'Drug therapies in severe asthma - the era of stratified medicine'. Together they form a unique fingerprint.

Cite this